Aslan Pharmaceuticals Ltd ADR (NASDAQ:ASLN) announced in July 2018 that it has received clinical trial authorization in Singapore to conduct a Phase I study of ASLAN004 for the treatment of atopic dermatitis (AD). The product is a monoclonal antibody targeting interleukin 13 receptor α 1 (IL13Rα1). The Phase I dosing study will consist of a single dose escalation in healthy volunteers and a multiple dose escalation in AD patients.
ASLAN004 mechanism previously validated
The target of ASLAN004 IL13Rα1 is a subunit of an interleukin receptor on the surface of macrophages that regulates their inflammatory and anti-inflammatory properties. The principle of targeting this receptor has already been tested in the form of the drug Dupixent (dupilumab, Regeneron/Sanofi), which inhibits the receptor’s other subunit IL4Rα1. The drug was approved in March 2017 for atopic dermatitis and had revenues of €219m that year.
To read the entire report Please click on the pdf File Below: